Scarica l'app Stockscreener
242.74
0.80%
1.92
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Precedente Chiudi:
$240.82
Aprire:
$241.63
Volume 24 ore:
776.05K
Relative Volume:
0.95
Capitalizzazione di mercato:
$17.08B
Reddito:
$2.36B
Utile/perdita netta:
$236.10M
Rapporto P/E:
73.87
EPS:
3.286
Flusso di cassa netto:
$382.50M
1 W Prestazione:
+0.33%
1M Prestazione:
-12.74%
6M Prestazione:
-21.36%
1 anno Prestazione:
-13.96%
Intervallo 1D:
$241.63
$249.73
Intervallo di 1 settimana:
$240.33
$255.71
Portata 52W:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Nome
Insulet Corporation
Settore
Industria
Telefono
978-600-7000
Indirizzo
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
242.74 | 16.94B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Ripresa | TD Cowen | Hold |
| 2026-01-12 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Iniziato | Evercore ISI | Outperform |
| 2025-11-19 | Aggiornamento | UBS | Neutral → Buy |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Ripresa | Oppenheimer | Outperform |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-05-13 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-07 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-11 | Downgrade | Citigroup | Buy → Neutral |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-07-28 | Iniziato | Wells Fargo | Overweight |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Iniziato | BofA/Merrill | Neutral |
| 2020-03-31 | Downgrade | Berenberg | Buy → Hold |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-10 | Iniziato | CFRA | Sell |
| 2019-10-23 | Iniziato | Stifel | Hold |
| 2019-10-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-10-04 | Downgrade | UBS | Buy → Neutral |
| 2019-10-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-04-20 | Iniziato | Berenberg | Buy |
| 2018-02-22 | Reiterato | Barclays | Overweight |
| 2018-01-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Iniziato | Barclays | Overweight |
Mostra tutto
Insulet Corporation Borsa (PODD) Ultime notizie
Insulet Expands Omnipod 5 To Middle East As Valuation Gap Persists - Yahoo Finance
Agree To Buy Insulet At $210, Earn 10.6% Annualized Using Options - Nasdaq
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market - Benzinga
ING Groep NV Grows Stock Holdings in Insulet Corporation $PODD - MarketBeat
Exploring Analyst Estimates for Insulet (PODD) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance
Impax Asset Management Group plc Invests $2.98 Million in Insulet Corporation $PODD - MarketBeat
Is Insulet Corporation’s growth already priced inWeekly Trade Report & Step-by-Step Trade Execution Guides - mfd.ru
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Candriam S.C.A. Sells 40,485 Shares of Insulet Corporation $PODD - MarketBeat
Insulet (PODD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Is Insulet Corporation forming bullish engulfing patternsAnalyst Upgrade & AI Powered Market Trend Analysis - mfd.ru
Insulet launches Omnipod 5 and Omnipod Discover in the Middle East to transform diabetes care - ZAWYA
ZAWYA-PRESSR: Insulet launches Omnipod 5 and Omnipod Discover in the Middle East to transform diabetes care - TradingView
Is Insulet (NASDAQ:PODD) Using Too Much Debt? - 富途牛牛
Published on: 2026-02-09 20:06:25 - baoquankhu1.vn
Insulet Corporation (PODD) Stock Analysis: Exploring 52.79% Potential Upside - DirectorsTalk Interviews
What Analysts Think Is Shifting The Story For Insulet (PODD) And Its Edge Now - Yahoo Finance
Aug Drivers: Is Insulet Corporation undervalued by DCF analysisJuly 2025 Momentum & Long-Term Growth Portfolio Plans - baoquankhu1.vn
BI Asset Management Fondsmaeglerselskab A S Buys 9,265 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Gets $15 Million Attorney Fees After Trade Secrets Win - Bloomberg Law News
Insulet Gets $14.9M Fee Award For Trade Secret Trial Win - Law360
Thrivent Financial for Lutherans Sells 9,253,606 Shares of Insulet Corporation $PODD - MarketBeat
Insulin Pump Market Insights $2.1B Revenue from Insulet, 500,000+ U.S. Users and 47.8% Adoption in Canada Driven by Government Funding - Yahoo Finance
Insulet Expands Omnipod Ecosystem As Shares Trade Below Analyst Targets - Sahm
Insulet launches automated insulin delivery system in Middle East to transform diabetes care - BioSpectrum Asia
Market Outlook: Can Insulet Corporation deliver alphaRate Cut & AI Enhanced Trading Alerts - baoquankhu1.vn
Insulet Launches Omnipod 5 Automated Insulin Delivery System in Middle East - marketscreener.com
Profit Review: Is Insulet Corporation undervalued by DCF analysisCPI Data & Target Return Focused Picks - baoquankhu1.vn
Insulet launches Omnipod 5 insulin system in Middle East - StreetInsider
User - The Chronicle-Journal
Insulin Delivery Devices Market to Reach US$ 43.11 Billion - openPR.com
Artificial Pancreas System Market is expected to reach US$ - openPR.com
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care - Yahoo Finance
Insulet Extends Key Supply Agreement with NXP USA - The Globe and Mail
Insulet’s Omnipod 5 Win for Type 2 Diabetes Reshapes Growth Outlook - Sahm
(PODD) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Stifel Adjusts Price Target on Insulet to $350 From $370, Maintains Buy Rating - marketscreener.com
Insulet (PODD) Maintains 'Buy' Rating as Target Price is Lowered to $350 | PODD Stock News - GuruFocus
18 Analysts Assess Insulet: What You Need To Know - Benzinga
Insulet Corp (NASDAQ:PODD) Matches Key Growth Rules in Navellier's "Little Book" Strategy - Chartmill
Allianz Asset Management GmbH Acquires 71,548 Shares of Insulet Corporation $PODD - MarketBeat
Machina Capital S.A.S. Makes New $2.78 Million Investment in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Extends Agreement with NXP USA, Inc. - GuruFocus
Insulet extends agreement with NXP, amends terms on pricing and volume - Investing.com Nigeria
Insulet extends agreement with NXP, amends terms on pricing and volume By Investing.com - Investing.com South Africa
Insulet Signs Purchase Agreement Addendum With NXP - TradingView
Insulet Corporation (PODD) Stock Analysis: A Compelling 44.81% Upside Potential for Investors - DirectorsTalk Interviews
Insulet Corporation (PODD): A Bull Case Theory - Insider Monkey
Reasons why hedge funds favor Insulet Corp (PODD) - MSN
Insulet Corporation $PODD Shares Sold by Knights of Columbus Asset Advisors LLC - MarketBeat
Bank of New York Mellon Corp Acquires 4,898 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation Azioni (PODD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.33%
0.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):